Wolfe Research initiated coverage on shares of Mylan (NASDAQ:MYL) in a research report released on Friday morning, Briefing.com Automated Import reports. The brokerage issued an outperform rating on the stock.
A number of other brokerages also recently commented on MYL. Morgan Stanley set a $70.00 target price on shares of Edison International and gave the stock a hold rating in a research note on Monday, July 15th. Zacks Investment Research downgraded shares of German American Bancorp. from a buy rating to a hold rating in a research note on Tuesday, April 30th. UBS Group reduced their target price on shares of Mylan to $23.00 and set a neutral rating on the stock in a research note on Tuesday, May 28th. Wells Fargo & Co downgraded shares of Mylan from an outperform rating to a market perform rating and reduced their target price for the stock from $33.00 to $22.00 in a research note on Tuesday, May 7th. Finally, Raymond James set a $31.00 target price on shares of Mylan and gave the stock a buy rating in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $33.65.
MYL opened at $18.10 on Friday. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $9.33 billion, a P/E ratio of 3.95, a price-to-earnings-growth ratio of 0.94 and a beta of 1.76. Mylan has a 52-week low of $16.63 and a 52-week high of $39.59. The firm’s fifty day moving average is $18.28.
Institutional investors and hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC increased its position in shares of Mylan by 107.1% during the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after acquiring an additional 500 shares during the last quarter. Pinnacle Bank grew its holdings in shares of Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after purchasing an additional 423 shares in the last quarter. Mascoma Wealth Management LLC acquired a new position in shares of Mylan in the first quarter valued at approximately $47,000. NuWave Investment Management LLC grew its holdings in shares of Mylan by 1,111.0% in the second quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock valued at $42,000 after purchasing an additional 2,011 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Mylan in the first quarter valued at approximately $87,000. Institutional investors and hedge funds own 83.77% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.